Key Highlights
- Shares rose 4.38% in pre-market trading to $91.91, up from a prior close of $88.05
- Company is scheduled to report second quarter fiscal 2026 results before market open the same day
- Analysts forecast adjusted EPS of $0.76 and Revenue of approximately $168.5 million for the quarter
- Company has beaten consensus estimates in three of the last seven quarters, including a first quarter beat of $0.52 versus $0.41 expected EPS
- 52-week range stands at $21.15 to $93.61, with a market Capitalization of $7.83 billion
Shares Gain Ahead of a Closely Watched Earnings Print
Liquidia (NASDAQ:LQDA) shares were trading at $91.91 in pre-market activity on August 12, 2026, up 4.38% from the prior close of $88.05. The move comes ahead of the company's second quarter fiscal 2026 earnings report, scheduled for release before market open the same day.
Analysts are forecasting adjusted Earnings Per Share of $0.76 and revenue of approximately $168.5 million for the quarter. The company has topped consensus estimates in three of its last seven reporting periods, most recently beating first quarter fiscal 2026 expectations with EPS of $0.52 against a $0.41 estimate and revenue of $132.9 million against a $119.4 million forecast.
What Liquidia Does
Liquidia is a Morrisville, North Carolina based biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its lead product, YUTREPIA, an inhaled dry powder formulation of treprostinil built on the company's proprietary PRINT particle-engineering technology, received full FDA approval in 2025 and now drives the majority of company revenue following its commercial launch. The company also markets a generic treprostinil injection in the United States and is advancing L606, a liposomal treprostinil formulation currently in Phase III trials.
What Investors Will Be Watching
Options market pricing implies a modest post-earnings move of roughly plus or minus 11%, close to the historical average reaction for the stock. Investors are likely to focus on the continued commercial ramp of the company's respiratory and pulmonary arterial hypertension product portfolio, Margin trends as YUTREPIA scales, and any updates related to ongoing Patent litigation with a competitor. Full-year 2026 EPS estimates have risen recently, from $2.97 to $3.02, and 2027 estimates have increased from $4.81 to $5.31, reflecting growing analyst confidence heading into the print.
Conclusion
Liquidia enters its second quarter fiscal 2026 report with shares already up in pre-market trading and a track record of beating estimates in recent quarters. With YUTREPIA now driving the bulk of revenue and analyst estimates trending higher for both this year and next, the earnings release itself, due before market open, will be the more meaningful catalyst for where shares head next. The company's pre-earnings gain reflects investor positioning ahead of that print rather than any new company-specific news.






Please wait processing your request...